Eric Meyerowitz, MD
Infectious Disease · Bronx, NYNPI 1841684727
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,113 of the $3,113 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Mannkind Corporation.
Across 1 payment — averaging $3112.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$3K
Across 62 payments — averaging $3841.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paratek Pharmaceuticals, Inc.$165K
- Modernatx, Inc.$73K
What the payments were for
- Speaking & faculty fees$3,113100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 1 | $3,113 |
How this compares
$3,113 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 285 | $1,072,254 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 29 | $451,881 |
| NuzyraOmadacycline Tosylate | 19 | $294,243 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 42 | $157,358 |
| JulucaDolutegravir/Rilpivirine | 18 | $61,765 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $57,792 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $46,916 |
| XifaxanRifaximin | 13 | $43,137 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $40,486 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $39,004 |
| PrezcobixDarunavir/Cobicistat | 13 | $32,329 |
| RybelsusSemaglutide | 20 | $18,499 |
| EliquisApixaban | 21 | $13,435 |
| JardianceEmpagliflozin | 19 | $13,134 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 27 | $10,895 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bronx
- Peter AlpertBronx$77K
- Norbert BrauBronx$57K
- Arturo CasadevallBronx$28K
- Dial HewlettBronx$27K
- Barry ZingmanBronx$24K
- Karen HennesseyBronx$16K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.